Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8678

Tetrafluoroethylene: Target Organs and Levels of Evidence for TR-450

Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CASRN 116-14-3) in F344 Rats and B6C3F1 Mice (Inhalation Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Tetrafluoroethylene
116-14-3		 Inhalation
0,312,625,1250,2500,5000 PPM/010 PER GROUP		 Battelle Northwest Laboratory

Levels of Evidence: None



Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Tetrafluoroethylene
116-14-3		 12/05/1995 Inhalation
MICE & FR: 0, 312, 625, OR 1250 MR: 0, 156, 312, OR 625 PPM; 50/GROUP		 Battelle Northwest Laboratory

Levels of Evidence

Male Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: SINGLE SECTIONS: ADENOMA 0/50 0/50 6/50 3/50 OR CARCINOMA 1/50 0/50 2/50 0/50 COMBINED 1/50 0/50 6/50 3/50; SINGLE AND STEP SECTIONS: ADENOMA 2/50 4/50 9/50 13/50 OR CARCINOMA 1/50 1/50 2/50 0/50 COMBINED 3/50 5/50 9/50 13/50
  • Liver: ADENOMA 3/50 6/50 8/50 5/50 OR CARCINOMA 1/50 1/50 10/50 3/50 COMBINED 4/50 7/50 15/50 8/50
May Have Been Related
  • Hematopoietic System: MONONUCLEAR CELL LEUKEMIA: 34/50 43/50 38/50 31/50
  • Testis: INTERSTITIAL CELL ADENOMA 39/50 40/50 48/50 47/50
Non-Neoplastic Lesions
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; TUBULE DEGENERATION; TUBULE HYPERPLASIA
Female Rats: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: SINGLE SECTIONS: ADENOMA 0/50 3/50 1/50 3/50 OR CARCINOMA 0/50 0/50 0/50 2/50 COMBINED 0/50 3/50 1/50 5/50; SINGLE AND STEP SECTIONS: ADENOMA 0/50 3/50 3/50 8/50 OR CARCINOMA 0/50 0/50 0/50 3/50 COMBINED 0/50 3/50 3/50 10/50
  • Liver: ADENOMA 0/50 4/50 5/50 6/50 OR CARCINOMA 0/50 4/50 9/50 2/50 COMBINED 0/50 7/50 12/50 8/50
  • Hematopoietic System: MONONUCLEAR CELL LEUKEMIA: 16/50 31/50 23/50 36/50
  • Vascular System (Liver): HEMANGIOSARCOMA 0/50 0/50 5/50 1/50
Non-Neoplastic Lesions
  • KIDNEY: TUBULE DEGENERATION; TUBULE HYPERPLASIA
  • LIVER: ANGIECTASIS
  • EYE: CATARACTS
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 17/48 17/48 12/48 20/48 OR CARCINOMA 11/48 20/48 33/48 26/48 COMBINED 26/48 34/48 39/48 35/48
  • Hematopoietic System: HISTIOCYTIC SARCOMA 0/48 12/48 7/48 7/48
  • Vascular System (Liver): HEMANGIOMA 0/48 10/48 5/48 2/48 OR HEMANGIOSARCOMA 0/48 21/48 27/48 37/48 COMBINED 0/48 26/48 30/48 38/48
Non-Neoplastic Lesions
  • KIDNEY: TUBULE DILATATION; TUBULE KARYOMEGALY
  • LIVER: ANGIECTASIS
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 15/48 17/48 20/47 15/47 OR CARCINOMA 4/48 28/48 22/47 20/47 COMBINED 17/48 33/48 29/47 28/47
  • Hematopoietic System: HISTIOCYTIC SARCOMA 1/48 21/48 19/47 18/48
  • Vascular System (Liver): HEMANGIOMA 0/48 5/48 2/47 1/47 OR HEMANGIOSARCOMA 0/48 27/48 27/47 34/47 COMBINED 0/48 31/48 28/47 35/47
Non-Neoplastic Lesions
  • KIDNEY: TUBULE KARYOMEGALY
  • LIVER: ANGIECTASIS; HEMATOPOIETIC CELL PROLIFERATION
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION